PCML
VKTX icon

Pavaki Capital Management LLC’s Viking Therapeutics VKTX Stock Holding History

Pavaki Capital Management LLC’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156K Hold
4,000
– – 0.05% 139
2026
Q1 		$130K Hold
4,000
– – 0.06% 141
2025
Q4 		$141K Buy
+4,000
New +$142K 0.06% 119

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM

Pavaki Capital Management LLC's VKTX Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 4,000 shares worth $156K. The position accounts for 0.05% of the portfolio, ranked #139.

Pavaki Capital Management LLC first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. 195 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Pavaki Capital Management LLC held 4,000 shares of Viking Therapeutics worth $156K as of Q2 2026.
  • Pavaki Capital Management LLC left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.05% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #139 holding.
  • Pavaki Capital Management LLC first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 195 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.